XSHE
002603
Market cap3.84bUSD
Oct 09, Last price
15.53CNY
1D
0.91%
1Q
0.13%
Jan 2017
26.16%
IPO
19.74%
Name
Shijiazhuang Yiling Pharmaceutical Co Ltd
Chart & performance
P/E
20.17
P/S
3.31
EPS
0.77
Div yield, %
1.95%
Shrs. gr., 5y
—
Rev. gr., 5y
-2.27%
Revenues
7.83b
+20.24%
Net income
1.29b
P
CFO
1.78b
+190.75%
Dividend
Jun 16, 20260.5 CNY/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Shijiazhuang Yiling Pharmaceutical Co., Ltd. engages in the research and development, production, and sale of Chinese medicine primarily in China. It offers drugs for cardiovascular and cerebrovascular, respiratory, endocrine, neurological, digestive, immune, and urinary diseases, diabetes mellitus, oncology, sleep-improving, and anti-aging. The company also provides dietary supplements, disinfection products, personal protective equipment, as well as formula granules. Shijiazhuang Yiling Pharmaceutical Co., Ltd. was founded in 1992 and is based in Shijiazhuang, China.
Key people
Yiling Wu
Honorary Chairman of the Board · since 2023
Chenguang Li
Finance Director, Director · since 2018
Xiangjun Wu
Chairman of the Board, General Manager · since 2023
Wei Wang
Deputy General Manager · since 2013
Keyuan Zhang
Deputy General Manager · since 2019
Xiaolin Zhou
Deputy General Manager · since 2023
Rui Wu
Secretary of the Board, Director · since 2016
Weidong Xu
Director · since 2020
Qiulian Zhang
Deputy General Manager, Director · since 2020
Shaohua Zhao
Director · since 2023
Zhenguo Chai
Independent Director · since 2024
Gang Chen
Independent Director · since 2023
Xiaohan Liu
Independent Director · since 2020
Headquarters & legal address
市石家庄市高新技术开发区天山大街２３８号
石家庄市, HE 100000
CN
石家庄市, HE 100000
CN
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||